Preventing and controlling influenza virus infection remains a global public health
challenge, as it causes seasonal epidemics to unexpected pandemics. These infections are …

Influenza viruses cause annual epidemics and occasional pandemics of respiratory tract
infections that produce a wide spectrum of clinical disease severity in humans. The novel …

Influenza is an acute viral respiratory infection that affects all age groups and is associated
with high mortality during pandemics, epidemics, and sporadic outbreaks. Nearly 10% of the …

Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza
drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a …

Influenza affects approximately 1 billion individuals each year resulting in between 290,000
and 650,000 deaths. Young children and immunocompromised individuals are at a …

Background Baloxavir marboxil (hereafter baloxavir), a selective inhibitor of influenza cap-
dependent endonuclease, was approved in 2018 in the USA and Japan for the treatment of …

Global analysis of the susceptibility of influenza viruses to neuraminidase (NA) inhibitors
(NAIs) and the polymerase acidic (PA) inhibitor (PAI) baloxavir was conducted by five World …

Effective antivirals provide crucial benefits during the early phase of an influenza pandemic,
when vaccines are still being developed and manufactured. Currently, two classes of viral …

Background Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA)
endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza …

This technical report accompanies the recommendations of the American Academy of
Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention …